Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14765

UPID:
STAT4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q14765; Q96NZ6

BACKGROUND:
The protein Signal transducer and activator of transcription 4, known as STAT4, plays a critical role in the immune system. It is essential for the differentiation of T-helper 1 cells and the production of interferon-gamma, key processes in immune defense. STAT4 activation occurs through phosphorylation in response to cytokines like IL12 and IFN-gamma, facilitating its nuclear translocation and gene activation role.

THERAPEUTIC SIGNIFICANCE:
The association of STAT4 with diseases such as systemic lupus erythematosus and rheumatoid arthritis highlights its significance in autoimmune disease pathogenesis. Targeting STAT4 for therapeutic intervention could revolutionize treatment strategies for these conditions. The exploration of STAT4's function and its impact on disease offers promising pathways for the development of targeted therapies, marking a significant step forward in autoimmune disease management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.